Headache and Migraine

This approval marks the third of its kind in the calcitonin gene-related peptide inhibitor class, starting with erenumab in May 2018.

Silberstein spoke about the new mechanism-based treatments that are revolutionary in changing the treatment landscape of migraine.

Neurology News Network for the week of September 22, 2018.

The monoclonal antibody is now the second member of the CGRP inhibitor class to be approved by the FDA.

The third-generation, small molecule CGRP antagonist is the second Biohaven migraine therapy to reach human clinical development.

The director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about the potential of a DHE therapy for acute migraine treatment.

A 33-year-old woman has been experiencing recurrent episodes of nausea, headaches, and dizziness for the past 8 months. She has come to the emergency department because she is concerned about her current episode, which is slightly different from her previous ones.

As a phase III trial of DHE gets underway, the director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about its clinical history in the United States.

A large study found an association between consumption of foods high in omega-3s and severe headache.

New research might make the case for a new headache subtype called “cochlear migraine.”

Neurologic complications remain a significant cause of long-term disability. Understanding and recognizing these conditions is crucial in effectively managing HIV.

Berk spoke to the important partnership between primary care and specialists in neurology.

With the pending decision on 2 more CGRP agents, the need for biomarkers to identify responders has never been greater.

Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.

Thomas Berk, MD, discussed the current therapeutic landscape of migraine, emphasizing the importance of conversing with each patient to identify an individualized approach.

David Dodick, MD, a neurologist at Mayo Clinic who’s been involved with multiple trials of headache medicines, provided further insight into the medication class.

Three studies explore how weather-related changes in migraine symptoms relate to atmospheric pressure, relative air humidity, and ambient temperature.

The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia said that for these patients, there are still many questions without answers.

How did erenumab's approval by the FDA change the landscape of migraine treatment?

The director of the Pediatric Headache Program at Children’s Hospital of Philadelphia spoke about the potential for CGRP inhibitors to find use in pediatric patients.

Robbins discusses the exciting future of true designer drugs in the works for migraine prevention as well as the challenges that remain in the space.

The nonselective ß-blocker proved efficacious in comparison with placebo in a pilot trial.

Stephen D. Silberstein, MD, discussed the powerful impact that the new class of CGRP inhibitors is beginning to have on migraine.

A 39-year-old male with a past medical history of hypertension and depression woke up with a severe headache, difficulty speaking, and right-sided weakness. Read the case details here.

Researchers sought to find whether the risk of later cerebrovascular events was associated with a hospital admission for migraine.